Introduction
Resistance of leukemic cells to chemotherapy is a major problem in the treatment of leukemia. Since most cytotoxic drugs mediate their cytolytic activity at least in part by incorporation into DNA during the S phase of the cell cycle, resistance may be caused by unresponsiveness of noncycling cells to these agents. 1 ,2 Therefore, alternative strategies are being explored using cell death induction pathways that are independent of the cell cycle status of leukemic cells.
Successful cellular immunotherapy of chemotherapy-resistant leukemia after allogeneic stem cell transplantation using donor lymphocyte infusions (DLIs) 3, 4 or leukemia-reactive cytotoxic T lymphocytes (CTLs) 5 has indicated that T lymphocytes may be able to eliminate chemotherapy-resistant leukemic cells, and that therefore T-cell-mediated tumor cell killing may be cell cycle independent. CTLs mediate tumor cell death by various effector mechanisms including a rapid destruction of the target cell by the perforin/granzyme pathway, or by the induction of target cell apoptosis through the interaction of Fas ligand (FasL) to the Fas receptor or TNF-a to the TNF receptor. 6 Crosslinking of Fas by either agonistic antibodies or natural FasL expressed on CTLs leads to trimerization of the receptor and activation of a signal cascade via the death-domain-containing adaptor Fasassociated death domain (FADD) and caspase-8 leading to the activation of downstream caspases, the effectors of cell death. 7, 8 Several studies reported on a possible influence of the cell cycle and proliferative status of leukemic cells on sensitivity to Fas-induced apoptosis. Komada et al. 9 described that induction of proliferation in acute monocytic leukemia (AML) cells resulted in increased cellular susceptibility to Fas-mediated apoptotic cell death and suggested a correlation between cell cycle arrest in early G 1 and resistance of AML to Fas-mediated cell death. In contrast, the study of Beletskaya et al 10 described that a human B-lymphoid cell line showed the highest sensitivity to Fas-induced apoptosis in G 1 phase of the cell cycle. Hueber et al 11 tested several leukemic cell lines, but observed no variation in cellular Fas sensitivity during cell cycle progression. However, the different definitions of resting cells in G 0 phase and activated cells in G 1 phase make it difficult to interpret and compare the results of these studies. In addition, the clinically observed relative nonresponsiveness of DLI in relapsed acute leukemia after transplantation as compared to chronic myeloid leukemia may even suggest a diminished susceptibility of rapidly proliferating cells for Fas-induced apoptosis by T cells. Although the exact relation between cell cycle status of leukemic cells and Fas-induced apoptosis remained unclear, we hypothesized based on these previous studies that therapeutic agents capable of altering the cell cycle status of leukemic cells may change the susceptibility of these cells to Fas-mediated apoptosis and immunotherapeutic interventions.
In this study, we manipulated different phases of the cell cycle and determined the sensitivity of leukemic cells to Fas-induced apoptosis in relation to the cell cycle status of the cells, using leukemic cell lines including the GM-CSF-dependent human myeloid leukemic cell line AML-193 as a model. 12 Not only reagents that induced complete progression through the cell cycle were analyzed. In addition, factors that allowed discrimination between resting cells in G 0 phase of the cell cycle and nonproliferating activated cells in G 1 phase were tested for their ability to manipulate Fas-induced cell death.
Interferon alpha (IFN-a) and interferon gamma (IFN-g) have a broad spectrum of activities including antiviral activity, effects on cellular metabolism, differentiation induction and inhibition of proliferation of (leukemic) precursor cells resulting in antitumor activity. 13 In chronic myeloid leukemia (CML) and hairy cell leukemia long-term IFN-a treatment has been used to induce remissions.
14 In part, the therapeutic effect of interferons may be directed via its antiproliferative effect, 13 but it may also cause an indirect immune-mediated effect by rendering the leukemic cells more susceptible to lysis by T cells. IFN-a appeared to amplify the effect of DLI after transplantation. 15, 16 Some studies have described increased Fas sensitivity of multiple myeloma cells, 17 monocytoid cells 18 and breast tumor cells 19 after interferon treatment, coincided by increased Fas expression. However, no cell cycle analysis was included in these studies.
We tested IFN-g and IFN-a for their effect on cell cycle distribution and proliferative capacity of AML-193 cells, and their potential to influence Fas-mediated apoptosis induction, without changing the Fas expression. In pilot experiments, we demonstrated that in contrast to short-term exposure to interferons, long-term treatment of leukemic cells with IFN-a or IFN-g resulted in distinct effects on proliferation, cell cycle status and Fas sensitivity of AML-193 cells.
Our results demonstrate that resting leukemic cells in G 0 phase as well as cycling cells in G 2 /M phase of the cell cycle are relatively resistant to Fas activation, whereas cells in G 1 are highly sensitive to Fas-induced cell death. We show that longterm treatment with interferons prevented AML-193 cells from entering the G 0 compartment in the absence of GM-CSF, and preserved an active cell cycle state of these cells. This activation step, without induction of proliferation, was sufficient to increase the sensitivity to Fas-induced apoptosis of noncycling cells.
Materials and methods

Cell lines
The human acute myeloid leukemia cell line Kasumi-1 was obtained from DSMZ GmbH (Braunschweig, Germany). The acute promyelocytic leukemia cell line HL-60, the myelomonocytic cell line U-937 and the GM-CSF-dependent AML cell line AML-193 12 were obtained from American Type Culture Collection (ATCC) (Rockville, MD, USA). The human acute lymphoblastic leukemia cell lines Leiden-ALL-HOP, Leiden-ALL-REL and Leiden-ALL-PHA, and the human CML blast crise cell line Leiden-CML-OF were generated in our laboratory, and were kindly provided by Dr B Nijmeijer.
All cell lines were cultured in serum-free medium consisting of IMDM (BioWhittaker, Verviers, Belgium) supplemented with 3 mM L-glutamine (BioWhittaker), antibiotics, 0.4% human serum albumin (HSA) (wt/vol) (CLB, Amsterdam, The Netherlands), 20 mg/ml cholesterol (Sigma-Aldrich, Zwijndrecht, The Netherlands), 20 mg/ml transferrin (Serva, Heidelberg, Germany), 5 Â 10 À5 M b-mercaptoethanol (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 10 mg/ml insulin (Sigma-Aldrich, Zwijndrecht, The Netherlands).
AML-193 cell line and culture conditions
AML-193 cells were cultured at 371C and 5% CO 2 in serum-free medium. Addition of 20 ng/ml recombinant human rhGM-CSF (Novartis, Bern, Switzerland) induced persistent proliferation of the cells. Three different sub cell lines were generated. The control cell line was cultured in the absence of interferons. The IFN-g cell line was maintained in a medium containing 1000 U/ ml IFN-g (Strathmann Biotech, Hannover, Germany), whereas the IFN-a cell line was maintained in a medium containing 500 U/ml IFN-a-2b (Schering-Plough, Amstelveen, The Netherlands). These three cell lines were expanded for at least 2 weeks in a medium containing 20 ng/ml GM-CSF. Growth factor deprivation of these lines was performed by washing the cells three times with phosphate-buffered saline (PBS), and subsequent culturing for at least 3 days in serum-free culture medium without GM-CSF. Flow cytometric analysis of intracellular Bcl-2, Bax and p53
Phenotypic analysis of surface expression
Cells were fixed in cold 1% paraformaldehyde for 15 min at 41C, and were then permeabilized in cold 70% methanol for 30 min at À201C. Cells were washed once with PBS, containing 0.8 g/l human albumin, and incubated with anti-Bax MoAb (Zymed, San Fransisco, USA), FITC-conjugated anti-Bcl-2 (Dako, Denmark), FITC-conjugated anti-p53 (Dako, Denmark) or isotype controls (BD)) for 30 min at 41C. After two washes, anti-Bax labeled cells were stained with PE-conjugated second antibody for 30 min at 41C. After additional washing, cells were resuspended, and analyzed using a BD FACScan and Cell Quest software (BD).
Proliferation assay
Cells were seeded at a concentration of 5000 cells per well in Ubottom 96-well microtiter plates in a final volume of 200 ml/ well. After various periods of culture, 3 H-thymidine (1 mCi/well) (Amersham Pharmacia Biotech Benelux, Roosendaal, The Netherlands) was added to the cultures. After 18 h of culture, the cells were harvested with an automatic microharvester, and counts per minute (cpm) were determined in a liquid scintillation counter.
Cell cycle analysis
For cell cycle analysis, 10 6 cells were washed with PBS, fixed, and permeabilized with 1% paraformaldehyde and 80 mg/ml Lalpha-lysolecithin (Sigma-Aldrich, Zwijndrecht, The Netherlands) for 10 min at 41C, washed twice with PBS containing 0.8 g/l human albumin, and stained with FITC-conjugated antiKi-67 MoAbs (clone MIB-1; Immunotech, Marseille, France) for 30 min at 41C. Isotype controls were stained in parallel. Cells were washed, and incubated with 20 mg/ml RNAse (Sentra Systems, Minneapolis, USA) for 15 min at 371C, and then stained with 20 mg/ml propidium iodide (PI) in PBS. Cells were subjected to flow cytometric analysis of DNA content using a Becton Dickinson flow cytometer. The percentages of cell cycle distribution were calculated by CellQuest software (BD).
To perform quantitative analysis of absolute numbers of cells in phases of the cell cycle after apoptosis induction, 200 000 cells were seeded in a total volume of 1 ml in 48-well plates, in a culture medium containing various cytokines in the presence or Cell-cycle-specific fas-induced apoptosis in leukemia I Jedema et al absence of 5 mg/ml FAS18. After 0, 24 and 40 h the cells were harvested and mixed with a fixed amount of Flow-Count Fluorospheres (Coulter Corporation, Miami, FL, USA). Cell cycle analysis was performed of the viable cells as described above and the absolute numbers of viable cells in each cell cycle fraction (G 0 , G 1 , S and G 2 /M) were calculated.
Apoptosis assay
Apoptosis was determined by Annexin V and PI staining. Cells were collected and resuspended in binding buffer (10 mM HEPES/NaOH pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 ) at a concentration of 10 6 cells/ml. Cells were incubated at room temperature for 30 min with 0.1 mg/ml FITClabeled Annexin V (Bender MedSystems, Vienna, Austria), washed and resuspended in binding buffer. PI was added at a final concentration of 1 mg/ml, and the cells were directly analyzed on a flowcytometer (Becton Dickinson (BD), San Jose, CA, USA).
Cytotoxicity assay
The cytotoxic activity of the apoptosis-inducing agonistic monoclonal antibody (MoAb) FAS18 (CLB, Amsterdam, The Netherlands) was measured using 24 or 40 h 51 Cr release assays. Target cells were labeled with 100 mCi of Na 2 51 CrO 4 (Amersham Pharmacia Biotech Benelux, Roosendaal, The Netherlands) for 60 min at 371C, washed two times with IMDM supplemented with 0.1% HSA, and resuspended in serum-free culture medium at a concentration of 1 Â 10 5 cells/ml. A volume of 100 ml target cells was added to 100 ml serum-free culture medium, containing 5 mg/ml FAS18 in a 96-well, U-bottom plate. Plates were incubated in a humidified atmosphere of 5% CO 2 and 371C. After 24 h, 25 ml of supernatant was harvested on solid scintillator-coated lumaplates (Packard, Groningen, The Netherlands), and counted in an automatic gamma counter (Topcount, Packard) (24 h assay). Plates were then incubated for another 16 h, and again 25 ml of supernatant was harvested and counted (40 h assay). For each target cell type, spontaneous release and maximal release was determined. The ratio of maximal to spontaneous release always exceeded 5. Percentage of lysis was calculated as follows:
percentage of specifix cytotoxicity ¼ experimental release ðcpmÞ À spontaneous release ðcpmÞ maximal release ðcpmÞ À spontaneous release ðcpmÞ
To determine the role of caspases in the induction of cell death as measured using the 51 Cr release assay, in selected experiments, after labeling of the cells with 51 Cr, cells were preincubated with 100 mM caspase family inhibitor 1 (Z-VAD-FMK, Alexis Biochemicals, Lausen, Switzerland) prior to apoptosis induction.
Results
Cell-cycle-specific Fas-induced apoptosis induction in leukemic cell lines
To investigate cell cycle specificity of Fas-induced apoptosis in leukemic cells, we tested a panel of leukemic cell lines. Detailed cell cycle analysis of surviving cells was performed after incubation in culture medium in the presence or absence of 5 mg/ml FAS18 agonistic anti-Fas antibodies, using flowcytometric analysis combining FITC-labeled anti-Ki-67 antibodies and PI DNA staining. A representative result of this analysis is shown in Figure 1 . The percentages of cells in G 0 /G 1 , S or G 2 /M phase were determined based on the DNA histogram (left figure). A gate (R1) was set for cells in G 0 /G 1 phase based on the DNA content. Double staining with Ki-67-FITC was used to discriminate between cells in resting G 0 and cells in activated G 1 phase. Cells in resting G 0 phase were defined as cells with no expression of the nuclear protein Ki-67 (right figure) . [20] [21] [22] [23] [24] We used the AML-193 leukemic cell line as a model to study cell cycle specificity of Fas-induced apoptosis, and analyzed the cell cycle distribution of the surviving cells after 40 h of apoptosis induction with FAS18 agonistic anti-Fas antibodies. As a control for cell-cycle-specific apoptosis induction, we used the S-phase-specific chemotherapeutic agent Ara-C. Ki-67/PI analysis was performed of cells cultured for 40 h in culture medium in the presence or absence of 5 mg/ml Figure 2B ). Cells in G 0 or S/G 2 /M phase appeared to be protected against Fas-induced apoptosis. As expected, after 40 h of treatment with the S-phase-specific cytostatic drug Ara-C, no cells in cycling S and G 2 /M phases were present in the viable population (Figure 2c) .
To determine the absolute numbers of cells in each cell cycle fraction (G 0 , G 1 , S and G 2 /M) that had undergone apoptosis in response to incubation with agonistic FAS18 antibodies, a fixed number of cells were incubated in a medium containing 5 mg/ml FAS18. After 0, 24 and 40 h, the cells were harvested and mixed with a fixed number of Flow-Count Fluorospheres. The absolute numbers of surviving cells in each cell cycle fraction and the percentages of cells that had undergone apoptosis in each cell cycle fraction were calculated. In Figure 2d the percentage viable cells in each cell cycle fraction is plotted after 24 and 40 h of Fas-mediated apoptosis induction. After 40 h of incubation, 86% of the cells in the G 1 compartment was deleted as compared to only 1% of the resting G 0 compartment. An increment of viable cells in S or G 2 /M to, respectively, 134 and 150% was seen after 40 h of Fas-mediated apoptosis induction.
In Table 1 the percentages of cells in G 0 , G 1 , S and G 2 /M phase of the cell cycle are listed for a panel of seven leukemic cell lines after 0 and 48 h of incubation in the presence of medium alone (M) or medium containing 5 mg/ml FAS18 (F). In all cell lines, the percentage of cells in G 1 phase of the cell cycle was selectively diminished after Fas-induced apoptosis, indicating G 1 specificity. Since these cell lines are all spontaneously proliferating, growth factor-independent cell lines, and therefore continuous progress through all phases of the cell cycle in time, long-term Fasmediated apoptosis induction results in deletion of all cells, complicating detailed analysis of cell cycle specificity.
Cytokine induced effects on AML-193 cells
To investigate in more detail the cell cycle specificity of Fasinduced apoptosis and the effect of separate cell cycle and proliferative status manipulation, we used the growth-factordependent human leukemic cell line AML-193 as a model. These cells are dependent on GM-CSF or IL-3 for proliferation but not survival. Three AML-193 subcell lines were generated by long-term culturing of AML-193 cells in the presence of GM-CSF alone, or in a medium containing GM-CSF supplemented with 1000 U/ml IFN-g or 500 U/ml IFN-a. Short-term (less than 1 week) treatment of serologically HLA-class II negative AML-193 cells with IFN-g, but not IFN-a, induced HLA-DR positivity. No other short-term effects of IFN-g and IFN-a on phenotype, proliferation and cell cycle status of AML-193 were found (data not shown).
In this study, we further analyzed the long-term effects of interferon treatment after more than 2 weeks. GM-CSF-deprived AML-193 cells cultured in serum-free medium without addition of growth factors and/or interferons were used as control cells. GM-CSF deprivation did not induce apoptosis. IFN treatment in the absence or presence of GM-CSF did also not lead to apoptosis induction. Flowcytometric analysis of control cells, IFN-g-and IFN-a-treated cells in the absence and presence of GM-CSF was performed to determine the expression of apoptosis-related proteins, adhesion molecules, TNF receptor 2 (TNF-R2), P-glycoprotein, and the costimulatory molecules CD40, CD80 and CD86. The results are summarized in Table 2 
Cell cycle analysis of AML-193 cells
The results of the cell cycle analysis by combined ki-67/PI DNA staining of the AML-193 cells cultured in the six defined culture conditions are illustrated in Figure 4 . Growth-factor-deprived control cells cultured in the absence of GM-CSF and interferons showed a high percentage (66%) of resting G 0 cells, 19% cells in G 1 and 15% of the cells in S or G 2 /M phase (n ¼ 20). Growthfactor-deprived cells treated with IFN-g or IFN-a showed higher percentages of activated G 1 cells (31 and 27%, respectively) and a lower percentage resting G 0 cells (48 and 55%, respectively). A small but significantly higher percentage of cells in S or G 2 /M phase was observed in IFN-g-treated cells (21%) and IFN-atreated cells (18%) as compared to control cells (Po0.01). Addition of GM-CSF to the culture medium caused high percentages of activated G 1 cells (46%) and cycling S or G 2 /M cells (34%), which was not affected by interferon treatment. Cr release assays. AML-193 cells were preincubated with 100 mM caspase inhibitors prior to apoptosis induction with agonistic anti-Fas antibodies. The mean percentages of lysis after 24 and 40 h of apoptosis induction in the absence of caspase inhibitors were 2573% and 3776%, respectively, and could be completely blocked by caspase inhibition resulting in 070.4% after 24 h and 075% after 40 h (n ¼ 4), illustrating that the Fas-mediated lysis measured in the Table 1 Cell cycle specificity of Fas-induced apoptosis in leukemic cell lines 
Effects of interferon treatment on Fas-mediated lysis
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Cr release assay was mediated by caspases and is therefore an appropriate assay to study apoptosis. Since the 51 Cr release assay was shown to be a reliable assay for quantitative analysis of cell death in our cell system, this assay was used in further experiments. Figure 5 illustrates the sensitivity of GM-CSFdeprived AML-193 cells cultured in the absence (control cells) or presence of interferons to Fas-mediated apoptosis induced by agonistic anti-Fas antibodies (FAS18). The results of all individual experiments are plotted as percentage-specific lysis after 24 h (Figure 5a ) or 40 h (Figure 5b ). The medians are indicated with bold lines. Incubation of control cells with 5 mg/ ml Fas 18 resulted in a median percentage specific lysis of 20% after 24 h and 26% after 40 h (n ¼ 40). A significant 2.5-fold increase in the median sensitivity to Fas-induced apoptosis was seen in the cells treated with IFN-g or IFN-a, resulting in 50% (n ¼ 25) and 53% (n ¼ 20) lysis after 24 h and 65 and 70% lysis after 40 h, respectively (Po0.001).
The effect of induction of proliferation by GM-CSF addition (20 ng/ml) on the sensitivity to Fas-induced apoptosis was investigated in cells cultured in the presence or absence of IFN-g or IFN-a. Lysis of the GM-CSF-treated cells was expressed as percentage of lysis as compared to GM-CSF-deprived cells. In comparison with control cells cultured in the absence of interferons, GM-CSF treatment resulted in a two fold higher sensitivity to Fas18 after 24 h (Figure 6a ) and 40 h (Figure 6b ). In contrast, no additional effect of GM-CSF addition on sensitivity to Fas-mediated lysis was observed in IFN-g-or IFN-a-treated cells.
To investigate whether the cell cycle status of leukemic cells at the onset of apoptosis induction affects the cell cycle specificity of Fas-induced apoptosis, we analyzed the cell cycle distribution of control and interferon-treated AML-193 cells in time after Fas-mediated apoptosis induction. In Table 3 , the percentages of cells in G 0 , G 1 , S and G 2 /M of the cell cycle are listed for control AML-193 cells and long-term IFN-g-or IFN-atreated AML-193 cells after 0 and 48 h of incubation in the presence of medium alone (M) or medium containing 5 mg/ml FAS18 (F). In all culture conditions, the percentage of cells in G 1 phase of the cell cycle was selectively diminished after Fasinduced apoptosis, indicating that the G 1 specificity of Fasinduced apoptosis is not influenced by the cell cycle status of the cells at the onset of apoptosis induction.
Discussion
To study in detail the cell cycle specificity of Fas-induced cell death in leukemic cells and the effects of manipulation of the cell cycle status of leukemic cells on the sensitivity to Cell-cycle-specific fas-induced apoptosis in leukemia I Jedema et al Fas-induced apoptosis, we developed a model using the GM-CSF-dependent myeloid leukemic cell line AML-193. Culturing of AML-193 cells in the absence of GM-CSF resulted in a slowly proliferating cell line, with the majority of the cells in resting G 0 phase of the cell cycle as defined by Ki-67/PI double staining [20] [21] [22] [23] [24] and confirmed by cyclin D3 Western blot analysis. In contrast to other factor-dependent cell lines, 25 growth factor deprivation of AML-193 cells did not induce apoptosis. Shortterm exposure to IFN-g or IFN-a did not have an effect on cell cycle distribution or proliferation status (data not shown). Longterm culturing of the cells in the presence of IFN-g or IFN-a did not induce direct apoptosis, but had an effect on cell cycle distribution, resulting in recruitment of cells from G 0 to G 1 of the cell cycle. The interferon effect was shown to be reversible, but it lasted at least 2 weeks to restore the original phenotype. In contrast to other studies in which increased Fas receptor expression was observed after interferon treatment, [17] [18] [19] phenotypic analysis of expression of apoptosis-related proteins, adhesion molecules and costimulatory molecules revealed no important differences.
We generated three different AML-193 subcell lines by culturing the cells in the presence of GM-CSF, GM-CSF+IFN-g or GM-CSF+IFN-a, and studied each of these cell lines in the presence or absence of GM-CSF. Cells cultured in these six culture conditions differed in cell cycle and proliferative status. IFN-g or IFN-a treatment in the absence of GM-CSF resulted in no induction of proliferation, but a significant shift from G 0 to G 1 phase of the cell cycle coinciding with a clear increase in sensitivity to Fas-induced apoptosis. A similar increase in sensitivity to Fas-mediated kill was observed by induction of proliferation of the cells with GM-CSF, independent of the presence of IFN-g or IFN-a in the culture medium. This indicated that the proliferation rate itself, as determined by complete progression through the cell cycle, did not coincide with the sensitivity to Fas-induced apoptosis, since the slowly proliferating IFN-a cell line was equally sensitive to the GM-CSF-or IFNg-treated cell lines.
Based on these findings and in concordance with the data described by Komada et al, 9 we conclude that Fas-mediated apoptosis induction is mainly restricted to leukemic cells in the G 1 phase of the cell cycle. However, in the study of Komada et al, no discrimination between G 0 and G 1 phase was made. As a control for cell-cycle-specific apoptosis induction, the Sphase-specific agent Ara-C was used. As shown in Figure 2 and Table 1 , G 1 specificity of Fas-induced apoptosis was also directly demonstrated by eradication of the G 1 compartment in time after Fas induction. Quantitative FACS analysis using FlowCount Fluorospheres was performed to calculate the absolute numbers of AML-193 cells that had undergone apoptosis in every cell cycle fraction. Similarly, eradication of activated G 1 cells after 40 h apoptosis induction with FAS18 was found. Resting G 0 cells were resistant against Fas-induced apoptosis. In addition, an increment of the percentage cells in S or G 2 /M phase was observed after induction with FAS18, suggesting diminished Fas sensitivity of these cycling cells. This same cell cycle specificity was observed in the panel of seven leukemic cell lines (Table 1) , although the results obtained for these growth factor-independent spontaneously proliferating cell lines were less explicit compared to the results obtained in the AML-193 cell line. This can be explained by the continuous cell cycle progression in these cell lines, resulting in ongoing forcing of cells from the resting G 0 compartment into the activated G 1 compartment, resulting eventually in deletion of all compartments.
The exact molecular mechanism(s) underlying the major differential sensitivity of cells in G 0 and G 1 phases for Fasinduced apoptosis are not clear. We speculate that the 'cell death resistance' of cells in resting G 0 phase of the cell cycle is a common phenomenon. An apoptosis induction process as induced by agonistic anti-Fas antibodies requires the apoptosis machinery of target cells. One could imagine that the proteins essential for mediating the cascade of events leading to apoptosis are downregulated in cells in resting G 0 phase of the cell cycle lacking RNA synthesis and displaying only minimal metabolic activity. From a biological point of view this makes sense, since hematopoietic cells in G 0 are likely to be of no danger to their environment and there is no direct need for preventive kill. Activation of the cells into G 1 phase and simultaneous induction of RNA synthesis significantly increases the efficiency of the cell death machinery. A possible explanation for the relative protection of cells in S or G 2 /M phase might be that the apoptosis machinery of cells in G 2 /M phase during actual cell division is not available to respond to death signals coming from the Fas receptor in the cell membrane. Apparently, the G 1 cells in the cell population were the main fraction sensitive to Fas-induced apoptosis. Studies using primary leukemic cells to analyze the long-term effects of interferons on cell cycle distribution and Fas susceptibility could not adequately be performed, since long-term in vitro culture of primary AML cells in the presence of interferons resulted in apoptosis in a significant proportion of the cells.
These results may be of clinical importance since long-term interferon treatment of patients with leukemia may decrease the percentage of resting tumor cells in G 0 phase, without the risk of inducing tumor cell proliferation and may in part explain the increased effect of IFN-a treatment in patients receiving DLI for relapsed leukemia after allogeneic stem cell transplantation. However, clinical studies are needed to not only determine the in vivo effect of interferon treatment on cell cycle distribution of leukemic cells, but also careful monitoring of toxic side effects will be needed in order to evaluate the effect of interferon treatment on nonleukemic cells.
In conclusion, we demonstrated G 1 -specific apoptosis induction in leukemic cells by agonistic anti-Fas antibodies. Recruitment of leukemic cells from the resting G 0 compartment Medium indicates incubation in serum-free culture medium; Fas indicates incubation in medium containing 5 mg/ml FAS18. Listed are the percentages of cells in G 0 , G 1 , S and G 2 /M phases of the cell cycle (n = 3).
Cell-cycle-specific fas-induced apoptosis in leukemia I Jedema et al into G 1 phase of the cell cycle using IFN-g or IFN-a treatment in the absence of GM-CSF was sufficient to increase the sensitivity to Fas-induced apoptosis, without induction of proliferation. Thus, interferon treatment may increase the effectiveness of immunotherapeutic interventions.
